Navigation Links
Building the future -- 21st century nano tools to repair the nervous system
Date:1/18/2008

This release is also available in French.

Rio Tinto Alcan reinforced its commitment to community involvement today with a $1-million donation to the Thinking Ahead Campaign at the Montreal Neurological Institute and Hospital (MNI), affiliated with McGill University and the McGill University Health Centre. The campaign is a five-year $40-million initiative to invest in people and expand facilities and services.

The donation, in support of the MNIs multidisciplinary NeuroEngineering program, was announced by Rio Tinto Alcan Chief Executive Richard Evans at Rio Tinto Alcans Montreal Headquarters. Mr. Evans is a member of the MNIs Thinking Ahead Campaign cabinet. David R. Colman, Director, MNI, said: We are proud that Rio Tinto Alcan and Dick Evans have chosen to invest in the MNI. Their support of the ground-breaking NeuroEngineering program gives us the opportunity to expand our research into new directions that we cant even imagine now - exploring and bringing together new disciplines and technologies that we hope will improve the quality of life for those debilitated by injury or neurological disease.

Rio Tinto Alcan believes in supporting inventive institutions and organizations in the communities where we are present, said Richard Evans, Chief Executive, Rio Tinto Alcan. Good health and strong healthcare facilities are key to a communitys success and growth. Supporting the MNIs innovative NeuroEngineering Program is another way that we can play a role in improving the quality of life of people in Quebec and around the world. Advancement in this area could lead to significant scientific and medical breakthroughs that benefit populations everywhere.

The NeuroEngineering Program is a truly synergistic effort in which neuroscientists are engaging physical scientists to work together on some of the most compelling, unsolved problems related to
'/>"/>

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
Montreal Neurological Institute and Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Building disease-beating wheat
2. Building blocks of life formed on Mars
3. Rebuilding the evolutionary history of HIV-1 unravels a complex loop
4. Building blocks of life
5. Oceans Past: A Guide to Oceans Future
6. Air quality forecasts see future in space
7. Setting a course for the future of tissue engineering
8. Methane from microbes: a fuel for the future
9. Sunbathing tree frogs future under a cloud
10. NASA technology helps predict and prevent future pandemic outbreaks
11. DOE publishes update of plan: Facilities for the Future of Science: A 20-Year Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10